Article

FDA approves trypan blue 0.15%

The FDA has approved trypan blue ophthalmic solution 0.15% (MembraneBlue, Dutch Ophthalmic Research Center International, b.v.) for use as an aid during vitrectomy procedures by staining the epiretinal membranes and, thereby, facilitating the removal of tissue, according to a prepared statement.

Exeter, NH

―The FDA has approved trypan blue ophthalmic solution 0.15% (MembraneBlue, Dutch Ophthalmic Research Center International, b.v.) for use as an aid during vitrectomy procedures by staining the epiretinal membranes and, thereby, facilitating the removal of tissue, according to a prepared statement.

Available in sterile, single-use, 2.25-ml syringes filled to a volume of 0.5 ml, trypan blue 0.15% is the first and only approved solution for this indication, the company said. It selectively stains epiretinal membranes during ophthalmic surgical vitrectomy procedures and is intended to be applied directly to areas where membranes could be present.

Previously, trypan blue ophthalmic solution 0.06% (VisionBlue) was the only stain approved by the FDA for the anterior capsule of the lens during capsulorhexis. According to the statement, with this new FDA approval, trypan blue 0.15% now provides vitreoretinal surgeons with a higher concentration of a sterile solution of the acid diazo group dye.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Steven R. Sarkisian, Jr., MD, ABO, speaks about glaucoma at the 2025 ASCRS annual meeting
© 2025 MJH Life Sciences

All rights reserved.